Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
National Defense Authorization Act for Fiscal Year 2026
Client: EISAI, INC. · Firm: ROBERTI ASSOCIATES CONSULTING, LLC
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
National Defense Authorization Act for Fiscal Year 2026
Client: EISAI, INC. · Firm: ROBERTI ASSOCIATES CONSULTING, LLC
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2026 · third_quarter · Q3
Issues related to coverage and reimbursement under Medicare.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2026 · second_quarter · Q2
Source: Senate LDA
National Defense Authorization Act for Fiscal Year 2026
Client: EISAI, INC. · Firm: ROBERTI ASSOCIATES CONSULTING, LLC
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
National Defense Authorization Act for Fiscal Year 2026
Client: EISAI, INC. · Firm: ROBERTI ASSOCIATES CONSULTING, LLC
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Issues related to coverage and reimbursement under Medicare.
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2026 · first_quarter · Q1
Issues related to coverage and reimbursement under Medicare.
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2025 · fourth_quarter · Q4
Issues related to coverage and reimbursement under Medicare.
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2025 · third_quarter · Q3
Issues related to coverage and reimbursement under Medicare.
BIOSECURE Act/S. Amdt. 3236 to S. 2296, the National Defense Authorization Act for FY2026.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2025 · second_quarter · Q2
Issues related to coverage and reimbursement under Medicare. Issues related to FDA's Tropical Disease Priority Review Voucher (PRV) Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2025 · first_quarter · Q1
Issues related to coverage and reimbursement under Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2024 · fourth_quarter · Q4
Issues related to coverage and reimbursement under Medicare. Issues related to FDA's Tropical Disease Priority Review Voucher (PRV) Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2024 · third_quarter · Q3
Issues related to coverage and reimbursement under Medicare. Issues related to FDA's Tropical Disease Priority Review Voucher (PRV) Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2024 · second_quarter · Q2
Issues related to coverage and reimbursement under Medicare. Issues related to FDA's Tropical Disease Priority Review Voucher (PRV) Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2024 · first_quarter · Q1
Issues related to coverage and reimbursement under Medicare. Issues related to FDA's Tropical Disease Priority Review Voucher (PRV) Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2023 · fourth_quarter · Q4
Issues related to coverage and reimbursement under Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2023 · third_quarter · Q3
Issues related to coverage and reimbursement under Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2023 · second_quarter · Q2
Issues related to coverage and reimbursement under Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2023 · first_quarter · Q1
Issues related to coverage and reimbursement under Medicare
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EISAI, INC. via ROBERTI ASSOCIATES CONSULTING, LLC
2023 · first_quarter · RR
Issues related to Medicare coverage and reimbursement.